Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.32 0.1099 +52.31%
CYTK $12.99 1.0699 +8.98%
ARRY $4.09 0.2900 +7.63%
IMNP $4.10 0.1400 +3.54%
VRML $3.00 0.1000 +3.45%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

AGIO $43.58 -2.7600 -5.96%
MEIP $8.58 -0.4900 -5.40%
OMED $25.96 -1.2200 -4.49%
CVM $1.22 -0.0500 -3.94%
MDVN $57.72 -2.3200 -3.86%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Higher Coffee Intake May Reduce Liver Cancer Risk

(AACR) Apr 9, 2014 - The more cups of coffee a person drank, the lower the risk for developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to results presented at the AACR Annual Meeting 2014.
read press release 



Milk Thistle Extract, Silibinin, Reduces Self-Renewal of Colorectal Cancer Stem Cells

(UCCC/In the Lab blog) Apr 7, 2014 - Colorectal cancer stem cells thrive in conditions of inflammation.
read article 



Prediagnosis Obesity Predicts Poor Outcome for Colorectal Cancer Patients, Even Those With a Tumor Marker Linked to Better Outcomes

(AACR) Apr 9, 2014 - High body mass index (BMI), an indicator of obesity, before a colorectal cancer diagnosis was associated with increased risk of death after diagnosis, even when tumors harbored the microsatellite instability (MSI) marker normally associated with better prognosis, according to results of a large prospective study at the AACR Annual Meeting 2014.
read press release 



Unexpected Results in Cancer Drug Trial

(University of Southampton [UK]) Apr 8, 2014 - Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.
read press release 



Chemo Might Give Certain Lung Cancer Patients an Edge

(U.S. News & World Report/HealthDay News) Apr 8, 2014 - Cancer specialists have been unsure about how best to treat certain patients with an advanced form of lung cancer.
read article 



FDA Halts Halozyme's Pancreatic Cancer Study

(Reuters) Apr 9, 2014 - Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial.
read article 



Small Slice of Doctors Account for Big Chunk of Medicare Costs

(Wall Street Journal) Apr 9, 2014 - A tiny sliver of doctors and other medical providers accounted for an outsize portion of Medicare's 2012 costs, according to an analysis of federal data that lays out details of physicians' billings.
read article (paid subscription required) 



Cancer-Fighter Juno Therapeutics Hits The Pause Button On Trial After Patient Deaths

(Forbes) Apr 8, 2014 - Over the weekend at the annual meeting of the American Association for Cancer Research, two of Juno’s founders revealed that two patient deaths had led them to stop giving new patients a new cell therapy until changes could be made to their clinical trial.
read article 



Zogenix Wins U.S. Approval for Pure Hydrocodone Pain Pill

(Bloomberg) Apr 8, 2014 - Zogenix Inc. won approval to sell the first painkiller made of pure hydrocodone as U.S. regulators recommended restrictions on popular combination treatments with the drug. The decision helped Zogenix shares climb the most in eight months.
read article 



Alkermes to Seek Schizophrenia Drug Approval After Trial Success

(Reuters) Apr 8, 2014 - Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent.
read article 



Gilead Aims to License Hepatitis C Drug to 3-4 Indian Firms

(Reuters) Apr 8, 2014 - Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.
read article 



Express Scripts Raises Pressure on Gilead to Cut Drug Price

(Washington Post/Bloomberg) Apr 8, 2014 - Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions a year in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.
read article (free registration required) 



Gilead Hepatitis C Treatment Designated for FDA Priority Review

(NASDAQ/Dow Jones Business News) Apr 7, 2014 - Gilead Sciences Inc. on Monday said the Food and Drug Administration has placed the company's new drug application for a hepatitis C treatment under priority review.
read article 



Daiichi Sankyo to Sell Troubled Ranbaxy

(Wall Street Journal) Apr 7, 2014 - Daiichi Sankyo, unable to remedy chronic regulatory problems at Indian generics maker Ranbaxy Laboratories, is selling its controlling stake in the company amid heightened U.S. scrutiny of safety lapses there.
read article (paid subscription required) 



Obama Administration Reverses Proposed Cut to Medicare Plans

(Washington Post/Wonkblog) Apr 7, 2014 - Medicare has reversed proposed payment cuts to private heath plans in the popular Medicare Advantage program for the second straight year amid strong pushback from health insurers and Capitol Hill.
read article (free registration required) 



CORRECTION - Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 Pan-RAF Inhibitor Created and Developed in Collaboration with Eli Lilly

(Deciphera Pharmaceuticals) Apr 7, 2014 - (Correction replaces previous link posted in OBR daily yesterday) Deciphera Pharmaceuticals today announced the initiation of a Phase 1 clinical trial of its pan-RAF inhibitor LY3009120 (DP-4978), under development in collaboration with Eli Lilly.
read corporate press release 



Stand Up To Cancer and the Farrah Fawcett Foundation Announce New HPV Translational Research Team Grant

(AACR) Apr 7, 2014 - Research efforts will investigate approaches to develop novel immune therapies for HPV-associated cancers; HPV and Anal Cancer Foundation contributes to support of team.
read press release 



New SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Announced

(AACR) Apr 7, 2014 - Stand Up To Cancer (SU2C), The Lustgarten Foundation, and the Fox Family Cancer Research Funding Trust, along with the American Association for Cancer Research (AACR), SU2C’s Scientific Partner, announced the formation of a Dream Team dedicated to pancreatic cancer research during a press event today at the AACR Annual Meeting 2014, held here April 5-9.
read press release 



American Association for Cancer Research Inaugurates New Leadership at 2014 Annual Meeting

(AACR) Apr 7, 2014 - The American Association for Cancer Research (AACR) welcomes Carlos L. Arteaga, M.D., as president of the organization for 2014-2015.
read press release 



AACR 2014: Where ‘Meaningful Advances’ Against Cancer Begin

(City of Hope) Apr 5, 2014 - With more than 6,000 findings being presented over a five-day period at the 105th AACR annual meeting, the amount of information can seem overwhelming.
read article 



Puma Falls on Disappointing Breast-Cancer Drug Results

(Bloomberg) Apr 7, 2014 - Puma Biotechnology Inc. plunged the most ever after a company-sponsored study found only a suggestion of benefit with its experimental drug for breast cancer in one group of women whose tumors are driven by a specific protein.
read article 



Pfizer Shares Drop Despite Positive Test for Breast-cancer Drug

(MarketWatch/Health Exchange blog) Apr 7, 2014 - Pfizer Inc. dropped 3% — a relatively large amount for a big pharma firm — on Monday despite seemingly positive test results for its breast-cancer treatment palbociclib.
read article 



Gene, Immune Therapy Help Cancer War

(San Diego Union-Tribune) Apr 7, 2014 - The war on cancer is getting some potent reinforcements, including a potentially broad-spectrum new weapon and genetically engineered immune cells with improved cancer-fighting abilities, speakers said at a major cancer research conference held this week in San Diego.
read article 



CancerCare® Announces Oncology Leader Patricia J. Goldsmith as CEO

(CancerCare) Apr 7, 2014 - Patricia Goldsmith to lead CancerCare, 70-year-old national nonprofit for people coping with cancer.
read press release 



CEO Roundtable on Cancer Launches the Project Data Sphere Initiative, A New Data Sharing and Analytic Platform for Cancer Patient Benefit

(Yahoo! Finance) Apr 8, 2014 - Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (www.ProjectDataSphere.org), with the goal of advancing research to improve the lives of cancer patients and their families around the world.
read article